# NCT03571321 (NCT03571321)

> Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03571321
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: University of Chicago
- Conditions: Acute Lymphoblastic Leukemia; ALL, Childhood; ALL
- Interventions: Ruxolitinib; Cyclophosphamide; Cytarabine; Mercaptopurine; Vincristine; Pegaspargase; Rituximab; Methotrexate (Intrathecal Administration); Methotrexate (Intravenous Administration); Dexamethasone; Doxorubicin; Thioguanine; Methotrexate Oral Product
- Enrollment: 15
- Primary outcome: Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given

## Indexed commentary on NCT03571321 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03571321